Docetaxel Overview

Docetaxel is a paclitaxel anti-tumor drug that is widely used in the treatment of breast cancer, non-small cell lung cancer, prostate cancer and other malignant tumors. It exerts anti-cancer effects by inhibiting microtubule depolymerization and blocking cell division. This article will start fromMechanism of action, clinical application, adverse reactions and manufacturerIt is developed in four aspects, focusing on its efficacy and safety, with authoritative data support.

Mechanism of action and pharmacological properties

Docetaxel passedStabilize microtubule structure, prevent cancer cell mitosis and induce apoptosis. Compared with paclitaxel, it has better water solubility and stronger anti-tumor activity. Research shows that docetaxelHER2-positive breast cancerandMetastatic castration-resistant prostate cancerThe efficacy is significant (reference: NCCN Guidelines). The common dosage form is injection, which needs to be used under the guidance of professional medical personnel.

Clinical applications and indications

Docetaxel is included in several international treatment guidelines, such as:

It should be noted that its use requires strict evaluation of the patient's liver function and bone marrow reserve function.

Adverse reactions and risk management

Common side effects includeMyelosuppression, allergic reactions, fluid retention. Conditioning regimens such as dexamethasone may reduce the risk. The Lancet Oncology 2019 pointed out that dose adjustment and personalized treatment can significantly improve patient tolerance. Manufacturers such asSanofi (trade name: Taxotere)and domestic Hengrui Medicine etc. all provide detailed medication guides.

Summary and Outlook

Docetaxel, as the cornerstone drug for cancer treatment, has clear efficacy but needs to be used in a standardized manner. Future research directions includeNanoformulation Developmentandcombination immunotherapyexploration. Patients should follow medical advice when taking medication and monitor adverse reactions regularly.

Quote sources:

1. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines
2. "The Lancet Oncology" 2019 special review of docetaxel
3. Sanofi Pharmaceuticals Taxotere Instructions (2023 Edition)
4. Hengrui Medicine Docetaxel Injection Approval Data (State Food and Drug Administration)